achd
academy
UPDATE

2nd INTERNATIONAL CONGRESS
of Adult Congenital Heart Disease

LJUBLJANA, SLOVENIA
29-30 September 2023

CONGRESS BOOK

www.achdacademy.com

WELCOME NOTE

Dear colleagues and friend,

We are delighted to welcome you to the ACHD Academy Update Meeting 2023, International meeting on Adult Congenital Heart Disease, hosted in the picturesque city of Ljubljana.

This meeting marks the fourth activity organized by the ACHD Academy, following the success of our previous events, including the 1st ACHD Academy Update Meeting 2021 in Split, Croatia, a remarkably brave undertaking considering the challenging circumstances posed by the Covid-19 pandemic, and two ACHD Academy Echo educational events, held both online and in person in Zagreb, Croatia.

This year in Ljubljana, over the next two days, we have prepared an exceptional program with stellar experts and leaders in the ACHD community.

ACHD Academy Update aim is to provide you with the latest updates and insights that will help improve the lives of individuals with congenital heart disease.

Moreover, we hope to bring you social and networking opportunity and encourage you to engage in discussions with your colleagues. It's during these moments that some of the most profound collaborations and friendships are born.

We are thrilled to have you in beautiful Ljubljana.

Assistant Prof Margarita Brida, MD, PhD FESC

ESC Chairperson Elect of Working Group on ACHD
ESC Chairperson of ACHD Study Group for Central and Southeastern Europe
Royal Brompton & Harefield Hospitals and Imperial College London, UK
Faculty of Medicine, University of Rijeka, Croatia

WELCOME NOTE

On behalf of the local organizer, the Slovenian society for congenital heart disease, it is with great pleasure that we extend to you a warm and heartfelt welcome to the ACHD Academy Update in Ljubljana, Slovenia, a 2nd International Congress on Adult Congenital Heart Disease.

We are delighted that you are joining us for this exciting event. We have gathered a lineup of distinguished international experts in the field of adult congenital heart disease who will share their insights, research, and experiences and provide a global perspective on the challenges in the management of adult congenital heart disease.

We encourage you to actively participate in the discussions and share your expertise. Your contribution is indispensable to make a positive impact on the care of our patients.

In addition to the scientific content, we hope to provide you with a great social gathering and networking opportunity, bringing togehter colleagues and friends from around the world.

We look forward to sharing knowledge, networking, and making meaningful strides in the field of ACHD. We hope you will enjoy the congress and your stay in the beautiful city of Ljubljana.

SLOVENIAN SOCIETY **for congenital heart disease**

Assistant Prof Katja Prokšelj, MD, PhD

President of Slovenian society for congenital heart disease
Division for structural and congenital heart disease - lead, Department of Cardiology, University Medical Centre Ljubljana, Slovenia
Faculty of Medicine, University of Ljubljana, Slovenia

CONGRESS DIRECTORS

Margarita Brida
CROATIA

Michael A Gatzoulis
UK

Katja Prokselj
SLOVENIA

Massimo Chessa
ITALY

FACULTY

1. Margarita Brida, United Kingdom
2. Werner Budts, Belgium
3. Massimo Chessa, Italy
4. Filippo Crea, Italy
5. Michele D`Alto, Italy
6. Gerhard Diller, Germany
7. Jure Dolenc, Slovenia
8. Željko Đurić, Croatia
9. Heng Ee Ling, United Kingdom
10. Andreas Eicken, Germany
11. Antonio Pastora Gallego Garcia De Vinuesa, Spain
12. Michael Gatzoulis, United Kingdom
13. George Giannakoulas, Greece
14. Vibeke Elisabeth Hjortdal, Denmark
15. Andreas Hoschtitzky, United Kingdom
16. Andrej Janež, Slovenia
17. Borut Jug, Slovenia
18. Alexander Kempny, United Kingdom
19. Nejc Pavšič, Slovenia
20. Gregor Poglajen, Slovenia
21. Katja Prokšelj, Slovenia
22. Michael Lawrence Rigby, United Kingdom
23. Timothy Roberts, Australia
24. Jolien Wesselina Roos-Hesselink, Netherlands
25. Berardo Sarubbi, Italy
26. Jolanda Sabatino, Italy
27. Bojan Vrtovec, Slovenia

GENERAL INFORMATION

VENUE AND ACCOMODATION:
Best Western Premier Hotel Slon
Slovenska Cesta 34
Ljubljana, Slovenia
+386 (1) 47 01 100

TECHNICAL CONGRESS ORGANIZER:
Filida-Travel Agency
Dore Pfanove 7
Zagreb, Croatia
+385 (1) 461 65 20
achd@filidatravel.hr
www.achdacademy.com

LOCAL ORGANIZER:

SLOVENIAN SOCIETY for congenital heart disease

Slovenian society for
congenital heart disease
Ljubljana, Slovenia
E-mail: slo.achd@gmail.com

Katja Prokšelj, Jure Dolenc,
Polona Kačar, Nejc Pavšič

OFFICIAL LANGUAGE:
English

REGISTRATION DESK:

Thursday, September 28th
16:00 – 18:00h

Friday, September 29th
07:00 – 17:00h

Saturday, September 30th
08:00 – 14:00h

POSTER AND EXHIBITION AREA:

Friday, September 29th
09:00 – 17:00h

Saturday, September 30th
09:00 – 14:00h



SCIENTIFIC PROGRAMME

FRIDAY, 29 September 2023

9.00-9.15	**Welcome Greeting** *Margarita Brida, Katja Prokselj*
9.15-11.00	**In the spotlight: Update Session 1 - *The Rise of Catheter Intervention in ACHD*** *Chairs: Michael Rigby, UK, Aleksander Kempny, UK*
9.15-9.40	Coarctation of the aorta and re-coarctation: From simple to hybrid (25') *Massimo Chessa, Italy*
9.40-10.05	Percutaneous pulmonary valve in the native RVOT: Who, when, how? (25') *Andreas Eicken, Germany*
10.05-10.30	TAVI in ACHD/bicuspid aortic valve & clipping in systemic right ventricle tricuspid valve: Nonsense or reality? (25') *Ee Ling Heng, UK*
10.30-10.55	The rise of catheter intervention in ACHD: The view from the Royal Brompton Hospital (25') *Aleksander Kempny, UK*
11.00-11.30	***Coffee break***
11.30-13.00	**In the spotlight: Update Session 2 - *Must know ACHD papers 'Cherry picked' the most important papers by editors' choice*** *Chairs: Filippo Crea, Italy, Margarita Brida, Croatia*
11.30-12.00	International Journal of Cardiology Congenital Heart Disease ACHD papers in the recent years (30') *Michael A Gatzoulis, UK, Editor-in-chief IJC CHD*
12.00-12.30	European Heart Journal ACHD papers in the recent years (30') *Filippo Crea, Italy, Editor-in-chief EHJ*
12.30-13.00	'Cherry picked' the most important ACHD papers worldwide in the recent years (30') *Gerhard P Diller, Germany, Associate Editor Heart*

13.00-14.00	***Lunch break***
14.00-15.20	**In the Spotlight: Update Session 3 - *Pros and Cons*** *Chairs: Michael A Gatzoulis, UK, Zeljko Djuric, Croatia, Berardo Sarubbi, Italy*
14.00-14.40	Prevention of acquired CV disease in ACHD, too little too late? (40') *Jolien Roos-Hesselink, The Netherlands (15'+5')* *vs.* *Werner Budts, Belgium (15'+5')*
14.40-15.20	Addressing native RVOT in repaired Tetralogy of Fallot: surgery versus intervention (40') *Andreas Hoschtitzky, UK Surgery (15'+5')* *vs.* *Aleksander Kempny, UK Interventions (15'+5')*
15.20-15.50	***Coffee break***
15.50-16.50	**In the Spotlight: Update Session 4** *Chairs: Gerhard P Diller, Germany, Pastora Gallego, Spain*
15.50-16.10	Adults with TGA after arterial switch operation: optimal long-term management (20') *Pastora Gallego, Spain*
16.10-16.35	Novelties in ACHD ESC Guidelines for Infective Endocarditis by Task Force member (25') *Margarita Brida, Croatia*
16.35-16.50	The role of selexipag in PAH treatment (15') *Katja Prokselj, Slovenia* Satellite symposium sponsored by Janssen
17.00	**Wrap-up Day 1**
19.30	**Get-to-Gether Dinner (optional)**

SCIENTIFIC PROGRAMME

SATURDAY, 30 September 2023

9.00-11.00	**Wake-up Update Session 5: *Complex ACHD simplified*** *Chairs: Michael A Gatzoulis, UK, Jolien Roos-Hesselink, the Netherlands, Andreas Hoschtitzky, UK, Jolanda Sabatino, Italy*
9.00-9.20	Novelties in ACHD from ESC 2022 Guidelines for Pulmonary Hypertension (20') *George Giannakoulas, Greece*
9.20-9.40	Adults with Fontan circulation: optimal long-term management (20') *Vibeke Hjortdal, Denmark*
9.40-10.00	Lessons learned on how to treat (and repair?) challenging shunts (20') *Michaele D'Alto, Italy*
10.00-10.20	Adults with systemic right ventricle: optimal long-term management (20') *Katja Prokselj, Slovenia*
10.20-10.40	Adults with Ebstein anomaly: optimal long-term management (20') *Tim Roberts, Australia*
10.40-11.00	His bundle pacing in ACHD: looking for the G-spot (20') *Berardo Sarubbi, Italy*
11.00-11.30	***Coffee break***

11.30-12.00	**Keynote lecture: *The Long and Winding Road - Climbing Olympus to ACHD*** *Michael Rigby, UK* *Chairs: Margarita Brida, Croatia, Massimo Chessa, Italy*
12.00-13.00	**Update Session 6: *Slovenian Cardiac Society - Heart failure in ACHD*** Chairs: Vrtovec Bojan, Jure Dolenc, Katja Prokselj, Slovenia
12.00-12.15	Drugs in ACHD Heart failure (15') Nejc Pavsic, Slovenia
12.15-12.30	Cardiac Assist Devices and transplantation in ACHD (15') *Vrtovec Bojan, Slovenia*
12.30-12.45	The potential of exercise and cardiac rehabilitation in ACHD (15') *Borut Jug, Slovenia*
12.45-13.00	Obesity and diabetes: An emerging problem in ACHD (15') *Andrej Janež, Slovenia*
13.00-13.15	The Challenge of Heart Failure: A Practical Approach to the Treatment of Heart Failure with SGLT2 Inhibitors (15') *Gregor Poglajen, Slovenia* *Satellite symposium sponsored by Boehringer Ingelheim*
13.15-13.45	**Session 7: *Top 5 Abstract Presentation & Awards*** *Chairs: Margarita Brida, Croatia, Werner Budts, Belgium*
13.45	**Meeting Closure**

ABSTRACTS

- **SURGICAL OUTCOMES OF ADULT CONGENITAL PATIENTS BY AN INTEGRATED CONGENITAL (PEDIATRIC-ADULT) HEART SURGERY TEAM IN AN INTEGRATED (PEDIATRIC-ADULT) HEART CENTER**

  Ziv Beckerman, MD, Douglas Overbey, MD, Jacob N. Schroder, MD, Carmelo A. Milano, MD, Joseph W. Turek, MD, PhD, MBA

- **CATASTROPHIC THROMBOTIC EVENTS IN A PATIENT WITH TRANSPOSITION OF THE GREAT ARTERIES, ATRIOVENTRICULAR SEPTAL DEFECT, A BLALOCK-TAUSSIG SHUNT, KARTAGENER SYNDROME WITH SITUS INVERSUS AND AUTOIMMUNE DISEASES**

  Ivana Krajnc, Kevin Pelicon, Katja Prokšelj, Borut Jug, Gregor Tratar
  [Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia / Department of Cardiology, University Medical Centre Ljubljana, Slovenia / Faculty of Medicine, University of Ljubljana, Slovenia]

- **GENETIC ETIOLOGY OF CONGENITAL HEART DEFECTS IN ADULTS - CIGM EXPERIENCE**

  A. Peterlin, K. Writzl, A. Maver, B. Peterlin
  [Institute of Histology and Embryology, Faculty of Medicine, University of Ljubljana, Slovenia / Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Slovenia]

- **PSYCHIATRIC CO-MORBIDITIES IN PATIENTS WITH CONGENITAL HEART DEFECTS**

  Sara H Lau Jensen, Soha Sabtiy, Thomas Werge, Vibeke E. Hjortdal, Dorte Mikkelsen

- **MYOCARDIAL ISCHEMIA IN PATIENTS WITH EISENMENGER SYNDROME**

  Nejc Pavsic, Rok Zbacnik, Pavel Berden, Polona Kacar, Jure Dolenc, Monika Stalc, Barbara Guzic Salobir, Katja Prokselj
  [Department of Cardiology, University Medical Center Ljubljana, Slovenia / Faculty of Medicine, University of Ljubljana, Slovenia / Institute of Radiology, University Medical Centre Ljubljana, Slovenia / Department of Nuclear Medicine, University Medical Centre Ljubljana, Slovenia]

- **BURDEN OF ARRHYTHMIAS AND EVENT FREE SURVIVAL IN 823 PATIENTS WITH EBSTIEN ANOMALY**

  Eckerström F, Hjortdal VE, Eriksson P, Dellborg M, Mandalenakis Z
  [Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen University Hospital, Denmark / Department of Clinical Medicine, Copenhagen University, Denmark

/ Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden / Adult Congenital Heart Disease Unit, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden)

- **THE USE OF ANTICOAGULANT TREATMENT IN FOUR PATIENTS WITH EISENMENGER SYNDROME – A CASE SERIES**

  Ivana Krajnc, Kevin Pelicon, Katja Prokšelj, Gregor Tratar
  (Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia / Department of Cardiology, University Medical Centre Ljubljana, Slovenia / Faculty of Medicine, University of Ljubljana, Slovenia)

- **DIFFERENCES IN QUALITY OF LIFE IN ADULTS WITH REPAIRED TETRALOGY OF FALLOT COMPARED TO POST-MYOCARDIAL INFARCTION PATIENTS**

  Kevin Pelicon, Ivana Krajnc, Katja Prokšelj, Borut Jug, Marko Novaković
  (Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia / Department of Cardiology, University Medical Centre Ljubljana, Slovenia / Faculty of Medicine, University of Ljubljana, Slovenia)

- **PROGNOSTIC VALUE OF THE ELECTROCARDIOGRAM IN PATIENTS WITH BICUSPID AORTIC VALVE DISEASE**

  Zoë A. Keuning, Paul .M. Hendriks, Jan A. Kors, Allard T. van den Hoven, Laurie W. Geenen, Jannet A. Eindhoven, Vivan J.M. Baggen, Judith A.A.E. Cupers, Robert M. Kauling, Jolien W. Roos-Hesselink, Annemien E. van den Bosch
  (Department of Cardiology and Department of Medical Informatics, Erasmus University Medical Center Rotterdam, the Netherlands)

- **HEART RATE: THE MOST ACCESSIBLE RISK INDICATOR IN ADULT CONGENITAL HEART DISEASE**

  Paul M. Hendriks, Annemien E. van den Bosch, Jan A. Kors, Laurie W. Geenen, Vivan J.M. Baggen, Jannet A. Eindhoven, Robert M. Kauling, Judith A.A.E. Cuypers, Eric Boersma, Jolien W. Roos Hesselink
  (Department of Cardiology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands / ERN GUARD Heart: European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart / Department of Medical Informatics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands / Department of Clinical epidemiology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands)

- **PERINATAL OUTCOMES AFTER IN UTERO ACE INHIBITOR EXPOSURE: DATA FROM THE ESC REGISTRY OF PREGNANCY AND CARDIAC DISEASE (ROPAC)**

  Anneroos van der Zande, Karishma P Ramlakhan, Roger Hall, Mark R Johnson, Jolien W Roos Hesselink, on behalf of the ROPAC Investigators group
  (Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands / Department of Obstetrics and Fetal Medicine, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands / Department of Cardiology, University of East Anglia, Norwich, United Kingdom / Department of Obstetric Medicine, Imperial College London, Kensington, London, United Kingdom)

- **OPTIMAL MANAGEMENT APPROACH FOR LEFT CORONARY ARTERY-RIGHT VENTRICLE FISTULA: A CASE REPORT**

  Aleksandra Nikolić, MD, PhD, Stefan Veljković, MD, Jovana Lakčević, MD, Darko Boljević, MD, Sanja Vučinić, RN, Sanja Kablar, RN, Milovan Bojić, MD, PhD
  (Cardiovascular Institute ''Dedinje'', Belgrade, Serbia / Faculty of Medicine, University of Belgrade, Belgrade, Serbia / Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina)

- **CORRECTIVE SURGERY IN ELDERLY PATIENTS: A NEW ERA FOR CONGENITAL HEART DISEASES?**

  Lotti R, MD, Gil Ad V, MD, Sessarego E, MD, Mascia G, MD, PhD, Trocchio G, MD, Santoro F, MD, Pomè G, MD, PhD, Cavalla F, MD, Della Bona R, MD, PhD, Porto I, MD, PhD
  (Cardiac Rehabilitation, Asl3, Genoa, Italy / DICATOV Cardiothoracic and Vascular department, San Martino Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy / Department of Internal Medicine and Medical Specialties (DIMI) Clinic of Cardiovascular Diseases, University of Genoa, Genoa Italy / Cardiology Unit, Istituto Giannina Gaslini, Genoa, Italy / Cardiac Surgery Unit, Istituto Giannina Gaslini, Genoa, Italy / Cardiothoracic department, Istituto Clinico di Alta Specialità (ICLAS), Rapallo, Italy)

- **LOWER LIMBS STRENGTH AND CARDIORESPIRATORY CAPACITY AMONG FONTAN PATIENTS**

  Lotti R, MD, Barbara C, MD, Porcile A, MD, PhD, Guglielmi G, MD, Clavario P, MD, Trocchio G, MD
  (Cardiac Rehabilitation, Asl3, Genoa, Italy / Cardiology Unit, IRCSS Istituto Giannina Gaslini , Genoa, Italy)

- **QUALITY OF LIFE IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE IN SLOVENIA**

  Melita Flander, Primož Holc, Katja Prokšelj
  [Department of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia / Faculty of Medicine, University of Ljubljana, Ljubljana Slovenia]

- **PERCUTANEOUS INTERVENTION ON AN INCIDENTALLY DISCOVERED PATENT DUCTUS ARTERIOSUS (PDA) LATER IN LIFE: WHAT COULD GO WRONG?**

  Blackman C, Joy E, Ebeid A, Velasco-Sanchez D, Bolger A, English K
  [Department of adult congenital heart disease, Leeds General Infirmary / Department of adult congenital heart disease, Glenfield Hospital Leicester]

- **PREVALENCE OF ELEVATED LDL C SERUM LEVELS AND IMPACT ON THE INCIDENCE OF CORONARY ARTERY DISEASE IN ACHD PATIENTS**

  Carmen Liguori, MD, Amalia Siracusa, MD, Antonio Orlando, MD, Rosa Franzese, MD, Nunzia Borrelli, MD, Rosaria Barracano, MD, Giancarlo Scognamiglio, MD, PhD, Berardo Sarubbi, MD, PhD
  [University of Campania Luigi Vanvitelli, Naples, Italy / Adult Congenital Heart Disease Unit, Monaldi Hospital, Naples, Italy]

- **SEQUENTIAL MRI EVALUATION OF LYMPHATIC ABNORMAL ITIES OVER THE COURSE OF FONTAN COMPLETION**

  Kelly B, Mohanakumar S, Ford B, Smith C, Pinto E, Biko M D, Hjortdal V, Dori Y
  [Department of Cardiothoracic & Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark / Jill and Mark Fishman Center for Lymphatic Disorders, Children's Hospital of Philadelphia, Philadelphia, USA / Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen, Denmark]

- **AUDIT OF THE OUTCOME OF TRANSITION OF PATIENTS FROM PAEDIATRIC CARDIOLOGY SERVICES AT CAMBRIDGE UNIVERSITY HOSPITAL INTO THE ADULT CONGENITAL HEART DISEASE SERVICE AT ROYAL PAPWORTH HOSPITAL**

  Carole Phoenix, ACHD Lead Nurse, Marina Hughes, Consultant Cardiologist RPH

- **KARTAGENER SYNDROME - ROLE OF MULTIMODALITY IMAGING**

  Fabio Kadum, MD, Jure Šeremet, MD, Željka Rubeša Miculinić, MD, Teodora Zaninović Jurjević, MD, PhD
  [Clinic for Cardiovascular Diseases, Clinical Hospital Center Rijeka, Rijeka, Croatia / University of Rijeka, Faculty of Medicine, Rijeka, Croatia]

SLOVENIA

Slovenia is a Central European country bordered by Italy to the west, Hungary to the northeast, Austria to the north, Croatia to the southeast and the Adriatic Sea to the southwest. Located between the Alps and the Adriatic Sea, Slovenia is often referred to as the "green heart of Europe", where everyone can find something for themselves. Ljubljana is the capital and the largest city of Slovenia. Other urban areas are Maribor, Celje, and Kranj.

One of the most charming places in Slovenia is Bled with its Alpine lake. On the island, in the middle of the lake, you can climb the 99 steps to stop at the historic chapel and ring the wishing bell. Another attraction, the magnificent Postojna cave is the most visited tourist cave in Europe. The 140-year-old cave railway guides you through the amazing underground network of karst corridors, galleries and halls, home to a rare Proteus species. The cave railway has been operating in the cave for 140 years. Predjama Castle, located near to Postojna Cave, is the largest cave castle in the world.

The climate is mostly influenced by the Adriatic Sea and the Alps. The coastal areas boast a Mediterranean climate with balmy winters, while the northeast has a continental climate with cold, snowy winters, and hot summers. Despite being one of the smallest European countries, Slovenia is home to many world-renowned athletes, including cycling legends Primož Roglič and Tadej Pogačar, outstanding climber Janja Garnbret, and the 2017 European basketball champions with amazing NBA player Luka Dončić. Whether you enjoy hiking in the Alps, swimming in the Adriatic Sea, exploring the caves in the Karst region, or tasting a glass of local wine with a view of the numerous perched villages of the Goriška Brda region, Slovenia is the perfect country to visit.

Key facts:

- Population: 2.1 million
- Area: 20,271 sq km
- Capital: Ljubljana
- Languages: Slovene, Italian, Hungarian
- Currency: Euro
- Highest peak: Triglav (2,864 m)

For more information visit: https://travelslovenia.org/ and https://www.slovenia.info/en

LJUBLJANA

Ljubljana is the capital and the largest city of Slovenia. With its 293,000 inhabitants, it may be one of the smallest European capitals, but that does not make it any less lively and vibrant compated to its larger companions.

Ljubljana looks back on a long and storied history. The first evidence of settlement dates back to around 2000 BC. Around 50 BC, the city was an important Roman settlement called Iulia Aemona, as evidenced by numerous archaeological discoveries that are still being excavated today. In the Middle Ages, the city's most important landmark, Ljubljana Castle, was built. It still stands on the hill above the city and with its Outlook Tower offers the most beautiful view of Ljubljana and its surroundings.

Ljubljana owes its current appearance mostly to the famous architect Jože Plečnik, whose vision shaped the city's unified and unique identity. Among his most notable works are the building of the Slovenian National and University Library, the Covered Market (part of the Central Market) and the Triple Bridge over the Ljubljanica River. The central or Prešeren Square is one of the few central squares in Europe that is not adorned by a political figure or a military hero, but rather by a poet. France Prešeren was one of the great Romantic poets of Europe and is best known for his sonnets. The poet's statue stands opposite the bust of Julija Primic, his great unrequited love, which is mounted on the façade of a building located on the other side of the square.

Ljubljana is a city that is never crowded, but also never boring. As the meeting point of four Slovenian regions, the city's many restaurants offer a wide selection of local delicacies and even better wines. Over 50,000 university students live here, giving the city its youthful appeal. In the end, Ljubljana is a city to which people often return, whether for professional reasons or for the pleasant memories of previous visits. And how could they not, when the word "love" is in the name Ljubljana itself, which sounds similar to "ljubljena" (beloved woman).

For more information visit: https://www.visitljubljana.com/en/visitors/

Gold sponsors:

Janssen
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

Boehringer Ingelheim

Silver sponsors:

CARDIO MEDICAL

Pfizer

Medtronic
Engineering the extraordinary

Bronze sponsors:

KRKA

lek
a Sandoz company

GE HealthCare

NOVARTIS

BUTTERS

Sponsors:

AstraZeneca

MSD
INVENTING FOR LIFE

VIATRIS

MEDICA

AMGEN

SERVIER
moved by you

KEFO

AVTOHIŠA MALGAJ
Ljubljana
www.avtohisamalgaj.si

NOTES

Prijazno za bolnika, v podporo srcu.

Sestava Ena tableta s podaljšanim sproščanjem vsebuje 375 mg, 500 mg ali 750 mg ranolazina. **Terapevtske indikacije** Tezulix je indiciran pri odraslih kot dodatno zdravljenje za simptomatsko zdravljenje bolnikov s stabilno angino pektoris, pri katerih bolezen ni ustrezno nadzorovana ali pa ne prenašajo prve izbire zdravljenja (npr. z antagonisti adrenergičnih receptorjev beta in/ali zaviralci kalcijevih kanalčkov). **Odmerjanje in način uporabe** Odmerjanje Priporočeni začetni odmerek je 375 mg ranolazina 2-krat na dan. Po 2 do 4 tednih je treba odmerek titrirati na 500 mg 2-krat na dan, potem pa, glede na bolnikov odziv, do priporočenega največjega odmerka 750 mg 2-krat na dan. Če se pri bolniku pojavijo neželeni učinki, povezani z zdravljenjem (npr. omotica, slabost ali bruhanje), je treba odmerek morda zmanjšati na 500 mg ali 375 mg 2-krat na dan. Če simptomi kljub temu ne izginejo, je treba zdravljenje ukiniti. Varnost in učinkovitost Tezulixa pri otrocih, mlajših od 18 let, nista bili dokazani. Podatkov ni na voljo. Način uporabe Tablete je treba pogoltniti cele, ne smejo se zdrobiti, zlomiti ali žvečiti. Jemljejo se lahko s hrano ali brez nje. **Kontraindikacije** Preobčutljivost za učinkovino ali katerokoli pomožno snov v zdravilu. Huda ledvična okvara (kreatininski očistek < 30 ml/min). Zmerna ali huda jetrna okvara. Sočasno jemanje močnih zaviralcev encima CYP3A4 (npr. itrakonazola, ketokonazola, vorikonazola, posakonazola, zaviralcev proteaze HIV, klaritromicina, telitromicina, nefazodona). Sočasno jemanje antiaritmikov razreda Ia (npr. kinidina) ali razreda III (npr. dofetilida, sotalola), razen amjodarona. **Posebna opozorila in previdnostni ukrepi** Pri bolnikih, ki jemljejo zmerne zaviralce encima CYP3A4 ali zaviralce P-gp, bolnikih z blago do zmerno ledvično okvaro (kreatininski očistek 30–80 ml/min), bolnikih z blago jetrno okvaro, starejših bolnikih, bolnikih z majhno telesno maso (≤ 60 kg), bolnikih z zmernim do hudim kongestivnim srčnim popuščanjem (III.–IV. razreda po razvrstitvi NYHA /New York Heart Association/) je pri predpisovanju ali povečevanju odmerka ranolazina potrebna previdnost. Pri bolnikih s kombinacijo teh dejavnikov se lahko pričakuje dodatna izpostavljenost. Verjetno se bodo pojavili od odmerka odvisni neželeni učinki. Če Tezulix jemljejo bolniki s kombinacijo navedenih dejavnikov, jih je treba redno spremljati glede morebitnih neželenih učinkov, zmanjšati odmerek in po potrebi ukiniti zdravljenje. Previdnost je potrebna pri bolnikih s prirojenim sindromom ali sindromom podaljšanega intervala QT v družinski anamnezi, pri bolnikih z znanim pridobljenim podaljšanjem intervala QT in pri bolnikih, zdravljenih z zdravili, ki vplivajo na dolžino intervala QTc. Ledvično delovanje se s starostjo slabša, zato ga je med zdravljenjem z ranolazinom pomembno redno preverjati. **Medsebojno delovanje z drugimi zdravili in druge oblike interakcij** Učinek drugih zdravil na ranolazin Zaviralci encima CYP3A4 (npr. diltiazem, eritromicin, flukonazol) in zaviralci P-gp (npr. ciklosporin, verapamil) povečajo koncentracijo ranolazina v plazmi, zato se lahko poveča tudi možnost pojava od odmerka odvisnih neželenih učinkov. Uvedbi Tezulixa se je treba izogibati med zdravljenjem z induktorji encima CYP3A4 (npr. rifampicina, fenitoina, fenobarbitala, karbamazepina, šentjanževke). Učinek ranolazina na druga zdravila Morda bo potrebna prilagoditev odmerka za CYP3A4 občutljivih substratov (npr. simvastatina, lovastatina) in substratov CYP3A4 z ozkim terapevtskim indeksom (npr. ciklosporina, takrolimusa, sirolimusa, everolimusa), saj lahko Tezulix poveča njihovo plazemsko koncentracijo. Pri sočasnem jemanju z digoksinom so poročali o povprečno 1,5-kratnem povečanju koncentracije digoksina v plazmi, zato je treba po začetku in koncu zdravljenja s Tezulixom spremljati ravni digoksina. **Plodnost, nosečnost in dojenje** Na voljo je malo podatkov o zdravljenju z ranolazinom pri nosečnicah. Študije na živalih so pokazale embriotoksičnost. Možno tveganje za ljudi ni znano. Zdravilo se ne sme jemati med nosečnostjo, razen če je nujno potrebno. Ni znano, ali se pri človeku ranolazin izloča v materino mleko. Tveganja za dojenega otroka ne moremo izključiti, zato se zdravilo med dojenjem ne sme jemati. **Vpliv na sposobnost vožnje in upravljanja strojev** Študij o vplivu Tezulixa na sposobnost za vožnjo in upravljanje strojev niso izvedli. Zdravilo lahko povzroči omotico, zamegljen vid, diplopijo, zmedenost, motnje v koordinaciji in halucinacije, kar lahko vpliva na sposobnost za vožnjo in upravljanje strojev. **Neželeni učinki** Pogosto se pojavijo omotica, glavobol, obstipacija, slabost, bruhanje in astenija. Ostali neželeni učinki so občasni, redki ali neznane pogostosti. **Imetnik dovoljenja za promet z zdravili** Krka, d. d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija. **Način izdajanja zdravila** Samo na zdravniški recept. **Oprema** 60 tablet s podaljšanim sproščanjem po 375 mg, 500 mg ali 750 mg ranolazina. **Datum zadnje revizije besedila** 23. 12. 2022.

Samo za strokovno javnost. Celoten povzetek glavnih značilnosti zdravila je objavljen na www.krka.si.

7/2023, Slovenija, 404102-2023, AA.

KRKA

Krka, d. d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija, www.krka.si

NOTES

PROVEN PERFORMANCE SIMPLY DELIVERED

Clinical Value of Melody Transcatheter Pulmonary Valve (TPV) Therapy for Right Ventricular Outflow Tract (RVOT) Conduit or Surgical Bioprosthetic Pulmonary Valve (BPV) Dysfunction

Melody™
Transcatheter Pulmonary Valve Therapy (TPV)



Medtronic

SAVE-THE-DATE

achd academy ECHO

Pre-meeting of the **EUROACHD 2024**

ESC European Society of Cardiology

3rd ECHOCARDIOGRAPHY IMAGING COURSE in Adult Congenital Heart Disease

LONDON, UNITED KINGDOM
14 April 2024

www.achdacademy.com